Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now? [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on BMY. Bristol-Myers Squibb Company's share was trading at $59.43 as of March 26th. BMY's trailing and forward P/E were 16.61 and 9.20 respectively according to Yahoo Finance. Is BMY a good stock to buy? Jirsak/Shutterstock.com Bristol Myers Squibb (BMY) is a leading global biopharmaceutical company with a diversified portfolio focused on oncology, immunology, and cardiovascular diseases, making it a reliable dividend-paying stock for long-term investors. The company has a 17-year streak of consecutive dividend increases, currently yielding 4.63% with an annual payout of $2.52 per share, supported by strong free cash flow and profitability. Read More: 15 AI Stocks That Are Quietly Making Investors Rich Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential BMY's established products, including Opdivo and Eliquis, generate stable revenues even amid patent expirations, while its growth portfolio
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by Guggenheim. They now have a $72.00 price target on the stock.MarketBeat
- Bristol Myers Squibb (BMY) had its price target raised by Cantor Fitzgerald from $45.00 to $54.00. They now have a "neutral" rating on the stock.MarketBeat
- How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- BMY's page on the SEC website